This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Y-39983

Mitsubishi Tanabe Pharma Corporation

Drug Names(s): SNJ-1656, SNJ1656, Y39983

Description: Y-39983 is a ROCK (rho-kinase) inhibitor.

Deal Structure: Mitsubishi Tanabe and Senju
In December 2000, Mitsubishi Tanabe concluded a contract with Senju whereby commercialization rights will be out-licensed to Senju who will cooperate in its development in Japan and overseas (except China, Taiwan, South Korea, and southeast Asia).

Partners: Senju Pharmaceutical Co., Ltd.


Y-39983 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug